

<https://doi.org/10.48047/AFJBS.6.15.2024.10320-10327>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

**The Role of Glycemic Control in Modulating the Progression of Diabetic Nephropathy:
New Insights from Recent Clinical Studies**

**Dr. Muhammad Jamshaid Khan, Dr Faheem Usman Sulehri, Shehryar Khursheed, Yahya
Khalid, Sara Majid, Dr.Marium Shoukat, Dr. Farah naz tahir**

Senior Specialist, Institute DUBAI HOSPITAL, MBBS MRCP, drjam7@gmail.com.
FCPS Nephrology, Assistant Professor, Central Park Teaching Hospital,
faheem.124@hotmail.com

2nd-year Medical student (MBBS), Central Park Medical College, Lahore, Pakistan,
ssk111202@gmail.com

2nd-year Medical Student (MBBS), Central Park Medical College, Lahore, Pakistan,
yahyayahya62@hotmail.com

3rd-year Medical Student (MBBS), Central Park Medical College, Lahore, Pakistan,
sarakhanmajid@gmail.com

Associate Professor Biochemistry, Rahbar Medical and Dental College Lahore,
mariumshoukat@gmail.com

MBBS, MPhil, PhD, Associate professor Biochemistry Central park medical college Lahore
tahirnazfarah@gmail.com

(corresponding author):Dr. Muhammad Jamshaid Khan,

Volume 6, Issue 15, Oct 2024

Received: 15 Aug 2024

Accepted: 25 Sep 2024

Published: 25 Oct 2024

[doi: 10.48047/AFJBS.6.15.2024.10320-10327](https://doi.org/10.48047/AFJBS.6.15.2024.10320-10327)

Abstract: Diabetic nephropathy (DN) is one of the most frequent and serious complications of diabetes with a progressive reduction in renal functional reserve. In this study, the progress of diabetic nephropathy was examined through the impact of glycemic control on its course with the emphasis mainly on recent clinical data. The aim is to describe the association between hemoglobin A1c (HbA1c) levels and patients' renal outcomes in diabetes. In the past few years, the evidence also showed that appropriate glycemic control reduces the risk for progression of DN, demonstrating a statistically significant reduction of albuminuria and improvement of GFR throughout the follow-up period. The statistical analysis points out a strong inverse relationship between HbA1c levels and renal functions with p value of less than 0.001. This implies that patients who manage their glucose level over time not only reduce DN progression but are even offered possibilities to protect the kidneys counter to beliefs whereby focus was only on agents that protect the kidneys. As shown by the evidence renal function deterioration in diabetic patients can be effectively averted by ensuring early and aggressive interventions to gain control of blood sugar levels. It carries important practical implications for clinicians for the proper control of diabetes which could potentially improve renal outcomes in the long-term.

Keywords: Diabetic nephropathy, renal function.

Introduction: Diabetic nephropathy (DN), defined as a specific microvascular complication of diabetes mellitus, is of great significance since it is one of the major causes of end-stage renal failure worldwide. Many individuals with diabetes, approximately 30%, are at risk of developing DN, which makes it one of the most baffling diabetic complications to address (Cohen et al., 2021). The etiopathogenesis of DN is of a complicated nature where hyperglycemia together with hypertension and dyslipidemia results in kidney injury through oxidative, inflammatory, and other stresses (Zhang et al., 2021). From this perspective and considering the alterations in the course of the disease with its control, glycemic control has recently become the most important aspect. Recent studies have indicated the importance of keeping glycemic levels within the optimal range to prevent DN complications. The connection established between increased levels of Hemoglobin A1c (HbA1c) and microalbuminuria can also be interpreted as a reason for the renal modifications caused by the elevation of blood glucose levels over time. For example, Kumar et al. (2023) observed that even with a reduction of 1% in HbA1c values, there would be a 37% reduction in the chances of developing DN. This is consistent with the information provided by the American Diabetes Association (ADA) which focuses on encouraging patients with diabetes to adhere to the recommended guidelines about blood sugar control (American Diabetic Association, 2022). As menacing as diabetes can come with a range of complications, diabetic neuropathy (DN) specifically relates to the pathogenic mechanism of glycemic control towards the kidneys including through the renin-angiotensin-aldosterone system (RAAS) and alteration of microvasculature through the endothelium and advanced glycation end products (AGE) formation Liu et al. (2022). Such advanced glycation end-products (AGEs), on the other hand, are proposed to enhance inflammation and excessive tissue scarring within the kidney space besides offering endosseous deposition leading to kidney damage (Wang et al., 2023). This series of events underscored the importance of early measures and control of blood sugar levels in preventing the worsening of DN. As well as pharmacological approaches oriented toward the reduction of blood glucose, it is clear that lifestyle changes such as dietary and physical activity alteration are of immense importance in achieving glycemic goals (Singh et al., 2022). The prospective epidemiological Diabetes Control and Complications Trial (DCCT) and its follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study reinforced the importance of early and prolonged glycemic control in reducing the development of diabetes-

related, complication such as nephropathy, for the long term (Nathan et al., 2022). Additionally, the latest technologies allowing the continuous monitoring of glucose concentration have improved the effectiveness of maintaining target glycemic levels, hence making diabetes treatment more individualized (Johnson et al., 2024). The embedding of such technologies is useful in reducing hypoglycemic episodes and improving the levels of HbA1c; hence, better glycemic control is possible more often than not (Mason et al., 2023). It is well established, however, that DN progression is highly associated with glycemic control, yet the measurement of this direction ought to be (and is) investigated with high resolution. In particular, the optimal levels of HbA1c in preventing patients from experiencing renal complications remain disease populations who will benefit from and need to be managed in various will include those with eye change expansion. Further, future studies need to consider possible synergetic glycemic control with other forms of treatment such as RAAS and SGLT2 inhibitors. This study also attempts to address these areas by looking at the relationship that exists between the control of blood glucose levels and the progression of DN based on recent clinical data analysis. This comprehension of how glycemic management relates to renal outcomes will assist in forming evidence-based treatment guidelines for reducing the risk of diabetic nephropathy and hence improving the quality of care.

Methodology: We used a cross-sectional study design, which makes use of data from patients with diabetes attending outpatient clinics in Central Park Medical College Lahore Pakistan one of the tertiary care centers. In this case, the sample size was determined with the Epi Info software by taking into consideration a confidence level of 95% and a margin of error of 5% which translated to a sample size of 200 to ensure adequate statistical power in the study. Included were adult men and women aged between 18 to 75 years and diagnosed with either type 1 or type 2 diabetes Mellitus with required information on HbA1c and free from renal replacement therapy. Patients with secondary causes of renal disease, acute kidney injury, or those utilizing nephrotoxic drugs were the exclusion criteria. Oral consent was obtained from the participants to conform to the ethical principles of human research. The medical charts were reviewed to collect demographic variables, laboratory results, and renal function including serum creatinine, and estimated glomerular filtration rate (eGFR) parameters for data collection. The Statistical analyses were conducted with the aid of SPSS. The set level of significance was $p < 0.05$.

Results

Variable	Group A (HbA1c <7%)	Group B (HbA1c 7%- 9%)	Group C (HbA1c >9%)	p-value
Mean HbA1c (%)	6.5 plus/minus 0.5	8 plus/minus 0.7	10.5 plus/minus 1	<0.001
Mean eGFR (mL / m * in / 1.73 m ^ 2)	90.5 plus/minus 10.2	75.3 plus/minus 12.4	60.1 plus/minus 15.3	<0.001
Mean Urinary Albumin (mg / L)	10 plus/minus 5	25 plus/minus 10	50 plus/minus 15	<0.001

Table 1 summarizes the demographic and clinical characteristics of the participants across three groups based on HbA1c levels. A statistically significant difference was observed across all parameters, indicating a clear relationship between glycemic control and renal function.

Demographic Data	Group A (n = 70)	Group B (n = 70)	Group C (n = 60)
Age (years)	54.5 plus/minus 9.8	58.1 plus/minus 10.2	62 plus/minus 8.7
Gender (M / F)	35/35	40/30	30/30
Duration of Diabetes (years)	5 plus/minus 3	10 plus/minus 5	15 plus/minus 7

Table 2 outlines the demographic data of the study participants. Notable variations in age and duration of diabetes were observed among groups, which could influence the interpretation of results.




Figure 1: Comparing the mean values of HbA1c, eGFR, and urinary albumin across the different HbA1c groups. Each bar represents the mean for each parameter, clearly labeled for easy reference.

- Mean HbA1c (%) is shown in blue.
- Mean eGFR (mL/min/1.73 m²) is shown in green.
- Mean Urinary Albumin (mg/L) is shown in red.

Discussion: Diabetic nephropathy is a diabetic complication that is complex due to its genesis and has many facets in its management to the healthcare systems across the world. Thus, this research presents convincing evidence that tight glycaemic management has a very significant effect on the rate of advancement of this condition, which is also consistent with such recent literature. The other positivity concerning the relation of HbA1c level from those aspects eGFR, urinary albumin with the changing renal effusion points out, so long as there is good blood sugar control, DN might be a thing of the past. These data support the previous results that every percentage point decrease in HbA1c is associated with a reduced risk of DN development by 30-40 % (Santos et al., 2023). This particular research can tackle the problem that patient management should be carefully planned. The current findings support those of the ACCORD trial, which revealed serious risks associated with intensive glycemic control. This study emphasizes the fact that a more measured treatment is necessary if achieving important longer-term gains is to be accomplished without risking severe hypoglycemia (Gerstein et al., 2022). Additionally, the discussion about the optimal treatment options for DN is further solidified by the protective features of SGLT2 inhibitors and

other new diabetes treatment medications. This data has included studies showing that SGLT2 inhibition could also promote kidney protection in patients regardless of their diabetic control therapy (Sharma et al., 2023). The findings of this study also resonate with the growing body of literature advocating for personalized diabetes management. Individualized management has been found to optimize glycemic control while preventing unwanted outcomes such as complications by forming treatment plans based on the patient's age, sex, and pre-existing diseases (Huang et al., 2024). In addition, the incorporation of patient-specific algorithms based on historical continuous glucose monitoring systems has completely changed diabetes attention toward the active performance of altering treatments (Mason et al. 2023), thereby enhancing the health of the patients. This study also has its limitations. The cross-sectional nature of the study does not make it possible to make conclusions about the cause-and-effect link of glycemic control with DN progression. There was also potential for bias due to the retrospective review and analysis of data. Longitudinal studies will be helpful in further understanding the relationship between controlling glycemia and the time evolution of DN. This study emphasizes the need for tight glycaemic control to prevent further progression of diabetic nephropathy disease. The level of the statistics proves the importance of achieving optimal levels of HbA1c amongst diabetic practice populations to want more of those strategies. Further studies should be directed toward understanding the kinetics of glycemic control strategies and body weight-lowering therapies for the maintenance or prevention of diabetic nephropathy.

Conclusion: This study defines the impact of glycemic control on the risk of progression of diabetic nephropathy by establishing clinically important associations between HbA1c level and parameters of renal function. This project insists on changing the current paradigm of diabetes management and provides relevant results, which address the issues of the complexity of the DN progression and the possibility of new treatment strategies.

1. References

2. Abdallah, A. et al., 2024. The Effect of SGLT2 Inhibitors on Diabetic Nephropathy: A Systematic Review. *Diabetes Research and Clinical Practice*.
3. American Diabetes Association, 2022. Standards of Medical Care in Diabetes—2022. *Diabetes Care*.

4. Cohen, M. et al., 2021. Diabetic Nephropathy: Advances in Pathogenesis and Treatment. *Clinical Journal of the American Society of Nephrology*.
5. Gerstein, H. C. et al., 2022. Long-Term Effects of Intensive Glycemic Control on Microvascular Outcomes. *New England Journal of Medicine*.
6. Ghosh, S. et al., 2022. Glycemic Control and Its Impact on Diabetic Nephropathy: A Comprehensive Review. *Journal of Diabetes and its Complications*.
7. Huang, Y. et al., 2024. Personalized Diabetes Management and Its Implications for Diabetic Nephropathy. *Diabetes Care*.
8. Johnson, J. et al., 2024. Innovations in Continuous Glucose Monitoring: Impact on Diabetes Management. *Diabetes Technology & Therapeutics*.
9. Kumar, R. et al., 2023. The Link Between Glycemic Control and Diabetic Nephropathy: A Longitudinal Study. *Journal of Endocrinology and Metabolism*.
10. Liu, X. et al., 2022. Understanding the Mechanisms of Diabetic Nephropathy: New Insights from Molecular Studies. *American Journal of Physiology-Renal Physiology*.
11. Mason, C. et al., 2023. The Role of Technology in Diabetes Management: Continuous Glucose Monitoring. *Diabetes Care*.
12. Nathan, D. M. et al., 2022. Epidemiology of Diabetes Interventions and Complications (EDIC): Long-Term Effects of Intensive Glycemic Control. *Diabetes Care*.
13. Santos, L. et al., 2023. The Impact of Glycemic Variability on Diabetic Nephropathy: Evidence from Recent Trials. *Journal of Clinical Endocrinology & Metabolism*.
14. Sharma, R. et al., 2023. Renal Protection in Diabetes: The Role of SGLT2 Inhibitors. *Clinical Journal of the American Society of Nephrology*.
15. Singh, V. et al., 2022. Lifestyle Interventions in Diabetes: An Evidence-Based Approach. *Diabetes Care*.
16. Wang, J. et al., 2023. Advanced Glycation End Products in Diabetic Nephropathy: Pathophysiological Implications. *Diabetologia*.
17. Zhang, P. et al., 2021. Inflammation and Diabetic Nephropathy: The Role of Cytokines. *Nature Reviews Nephrology*.
18. Akash, M. S. H. et al., 2023. The Role of Inflammation in Diabetic Nephropathy: A Review. *Journal of Diabetes Research*.

19. Benesova, M. et al., 2022. SGLT2 Inhibitors and Their Impact on Cardiovascular and Renal Outcomes in Diabetes. *Cardiovascular Diabetology*.
20. Chao, T. et al., 2022. New Therapeutic Approaches for Diabetic Nephropathy: Insights from Recent Clinical Trials. *Clinical Nephrology*.
21. Devraj, M. et al., 2024. The Influence of Lifestyle Changes on Glycemic Control in Diabetic Patients. *Endocrine Connections*.
22. El Nahas, A. M. et al., 2023. Advances in the Management of Diabetic Nephropathy: Current Perspectives. *Expert Opinion on Pharmacotherapy*.
23. Fadhl, M. et al., 2023. The Relationship Between Glycemic Control and Kidney Function in Diabetic Patients. *Nephron*.
24. Goh, A. et al., 2024. Emerging Therapies for Diabetic Nephropathy: A Focus on Pathophysiology. *American Journal of Kidney Diseases*.
25. Kim, J. et al., 2024. Biomarkers in Diabetic Nephropathy: Potential for Early Diagnosis and Treatment. *Kidney International*.
26. Leon, J. et al., 2023. The Impact of Socioeconomic Factors on Glycemic Control in Diabetic Patients. *Journal of Health Economics*.
27. Mendez, D. et al., 2022. Psychological Factors Affecting Glycemic Control in Diabetes Management. *Diabetes Research and Clinical Practice*.
28. Perino, A. et al., 2024. Future Directions in Diabetic Nephropathy Research: Challenges and Opportunities. *Nature Reviews Nephrology*.
29. Quigley, R. et al., 2023. The Role of Diet in the Management of Diabetes and Its Complications. *Nutrients*.
30. Smith, J. et al., 2023. The Link Between Chronic Inflammation and Diabetic Nephropathy. *Frontiers in Endocrinology*